

Online Resource for:

Pragmatic modeling supports current dosing guidelines for carbamazepine and valproic acid for the treatment of epilepsy in children

Joyce E.M. van der Heijden¹, Violette Gijsen¹, Anne M. van Uden¹, Marika de Hoop-Sommen¹, Jolien J.M. Freriksen¹, Elke Jacobs², Rick Greupink¹, Saskia N. de Wildt^{1,3}

¹*Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud university medical center, Nijmegen, The Netherlands;* ²*HagaZiekenhuis-Juliana's Childrens hospital;* ³*Department of Neonatal and Pediatric Intensive Care, Division of Pediatric Intensive care, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands*

Corresponding author – Prof. dr. Saskia N. de Wildt, Saskia.deWildt@radboudumc.nl.

Content

1. Search strategy	2
2. Pharmacokinetic studies	6
3. Model input parameters	2
4. Model verification	12
5. Simulating untested dosing regimens	32
6. References	37

1. Model input parameters

Table 1. Drug-dependent input parameters for carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE)

	Parameter	CBZ	CBZE
Physicochemical properties	Molecular weight (g/mol)	236.27	252.27
	Neutral species octanol : buffer partition coefficient (Log P _{o:w})	2.22	1.44
	Compound type	Neutral	Neutral
	Blood-to-plasma partition ratio (B/P)	1.07	1.53
	Fraction unbound (f _u)	0.25	0.48
	Plasma binding protein	HSA	HSA
	Absorption	Absorption model	First-order absorption
Fraction available from dosage form (f _a)		0.84	0.84
First order absorption rate constant (k _a ; 1/h)		0.5	0.19
Lag time (h)		0	0
Unbound fraction of drug in enterocytes (f _{u_{gut}})		1	1
A nominal flow in gut model (Q _{gut} ; L/h)		14.419 (P)	
Human jejunum effective permeability (P _{eff,man} ; 10 ⁻⁴ cm/s)		4.3	1.7787 (P)
Permeability Assay; values			PSA (Å ²); 58.9, HBD; 2
Distribution	Distribution model	Minimal PBPK model	Minimal PBPK model
	Volume of distribution at steady state (V _{ss} ; L/kg)	0.78 (30% CV)	0.78 (30% CV)
Elimination	Oral clearance (CL _{po}) (L/h)		6.07 (36 % CV)
	CYP3A4 – 10,11-epoxidation (V _{max} ; K _m)	0.72; 180.2	
	CYP3A5 – 10,11-epoxidation (V _{max} ; K _m)	1.44; 332.3	
	CYP2C8 – 10,11-epoxidation (V _{max} ; K _m)	0.03; 741.74	
	CYP3A4 – Additional Inducible (CL _{int})	0.0106	
	UGT2B7 – N-glucuronidation (V _{max} ; K _m ; f _{mic})	0.79; 126.9; 0.2	
	rUGT Scalar (Liver; Intestine; Kidney)	5.29; 0.63; 0.85	
	Additional Liver CL (HLM) (μL/min/mg protein)	0.255	
Interaction	Typical renal clearance (CL _R) (L/h)	0.0084	0.14
	CYP3A4 - Ind _{slope} [^] ; CV (%); f _{u_{inc}}	0.16; 30; 1	0.14; 30; 1
	CYP3A5 - Ind _{slope} [^] ; CV (%); f _{u_{inc}}	0.16; 30; 1	0.14; 30; 1

Table 2. Drug-dependent input parameters for valproic acid (VPA) immediate-release (IR), VPA extended release (ER), and 4-ene-VPA

	Parameter	VPA IR (1)	4-ene-VPA (1)	VPA ER (2)
Physicochemical properties	MW (g/mol)	144.21	142.2	144.211
	Log P _{0:w}	2.75	2.21	2.75
	pKa	4.8	5.06	4.8
	Compound type	Monoprotic acid	Monoprotic acid	Monoprotic acid
	B/P	0.55	0.55	0.55
	Concentration dependent fu*	0.07-0.15 (3)	0.0567 (P)	0.07-0.15 (3)
	Plasma binding protein	HSA	HSA	HSA
Absorption	Absorption model	First-order		ADAM
	Fa	1		
	ka (1/h)	VPA = 2 NaVPA / DVS = 4.1		
	Lag time (h)	EC tablets = 2		
	f _{gut}	1		
	Q _{gut} (L/h)	16.0 (P)		
	P _{eff,man} (10 ⁻⁴ cm/s)	5.8304 (P)		3.84 (P)
	Permeability Assay; values	PSA (Å ²); 37.3, HBD; 1		Caco-2 (6.5:7.4); 22.6, reference; propranolol, Caco-2 (6.5:7.4); 21.5
	Distribution	Distribution model	Minimal	Minimal
k _{in} (1/h), k _{out} (1/h), V _{sac} (L/kg)		0.217, 0.866, 0.036		0.217, 0.866, 0.036
V _{ss} (L/kg) Adult		0.10843	0.209	0.14
V _{ss} (L/kg) Pediatric, Kp Scalar		0.19001, 2.254		
Elimination	IV clearance (CL _{IV}) (L/h)		2.601	0.52
	rUGT Scalar	0.37		0.23
	UGT1A3 (V _{max} ; K _m)	600; 6400		600; 6400
	UGT1A4 (V _{max} ; K _m)	400; 3100		400; 3100
	UGT1A6 (V _{max} ; K _m)	700; 3200		700; 3200
	UGT1A8 (V _{max} ; K _m)	870; 5900		870; 5900
	UGT1A9 (V _{max} ; K _m)	960; 6300		960; 6300
	UGT1A10 (V _{max} ; K _m)	880; 5500		880; 5500
	UGT2B7 (V _{max} ; K _m)	1200; 1400		1200; 1400
	CYP2C9 – 4-ene-VPA (CL _{int}), fm	0.0003976, 0.00785		0.0015
	CYP2C9 – Other (CL _{int}), fm	0.0026609, 0.05255		
	Additional hepatic CL _{int}	0.2		0.125
	CL _{add} (L/h)		0.3414	
	CL _R (L/h)	0.0079	2.2596	0.0052

*Interpolation method: Piecewise Cubic Polynomial. Abbreviations: divalproex sodium (DVS), sodium valproate (NaVPA).




Figure 1. CYP and UGT ontogeny profiles. Equations: CYP2C8 activity below 20 years = $0.41 + (((1.053 - 0.41) * \text{Age}^{0.68}) / (0.366^{0.68} + \text{Age}^{0.68}))$; CYP2C9 activity below 5 years = $0.17 + (((0.98 - 0.17) * \text{Age}^{0.53}) / (0.0157^{0.53} + \text{Age}^{0.53}))$; CYP3A4 activity below 2.5 years = $0.15 + (((1.7 - 0.15) * \text{Age}^{1.3}) / (0.1^{1.3} + \text{Age}^{1.3}))$ and CYP3A4 activity above 2.5 years = $0.7 + 1 * \exp^{-0.01 * (\text{Age} - 0.5)}$; UGT1A4 activity below 20 years = $0.05 + (((1.028 - 0.05) * \text{Age}^{1.36}) / (1.042^{1.36} + \text{Age}^{1.36}))$; UGT1A6 activity below 15 years = $0.142 + (((1.025 - 0.142) * \text{Age}^{0.97}) / (0.411^{0.97} + \text{Age}^{0.97}))$; UGT1A9 activity below 0.16 years = $0.0541 + (((1.012 - 0.0541) * \text{Age}^{5.771}) / (0.07228^{5.771} + \text{Age}^{5.771}))$; UGT2B7 activity below 21 years = $0.113 + 0.0425 * \text{Age}$.

2. Search strategies

The PubMed database was searched for carbamazepine (CBZ) and valproic acid (VPA) adult and pediatric pharmacokinetic (PK) data. Both the drugname and brandname are included in the search queries. For CBZ the terms 'Carbamazepine' and 'Tegretol' were included and for VPA the terms 'Valproic Acid', 'Depakine', 'Depakote', 'Valproate', and 'VPA' Titles and abstracts of all search results were screened to check if actual PK data were provided in the publication. To extend our search strategy, the 'Similar articles' overview and references were checked to identify relevant articles which were missed with the initial search queries.

Search query for healthy volunteer PK studies:

((Pharmacokinet*[Title/Abstract]) AND (**DRUGNAME***[Title] OR **BRANDNAME***[Title]) AND (Healthy[Title] OR volunteer*[Title] OR adult*[Title] OR subject*[Title] OR Man[Title] OR Men[Title] OR Woman[Title] OR Women[Title] OR male*[Title] OR female*[Title])) OR ("Pharmacokinetics of"[Title]) AND ("**DRUGNAME**"[Title] OR "**BRANDNAME**"[Title]) OR ("**DRUGNAME** pharmacokinetics"[Title]))

CBZ → 176 results (01-08-2023)

VPA → 264 results (19-12-2023)

Search query for pediatric PK studies:

(Pharmacokinet*[Title/Abstract]) AND (**DRUGNAME***[Title] OR **BRANDNAME***[Title]) AND (Infan*[Title] OR newborn*[Title] OR new-born*[Title] OR perinat*[Title] OR neonat*[Title] OR baby[Title] OR baby*[Title] OR babies[Title] OR prematur*[Title] OR preterm*[Title] OR toddler*[Title] OR minors[Title] OR minors*[Title] OR boy[Title] OR boys[Title] OR boyfriend[Title] OR boyhood[Title] OR girl*[Title] OR kid[Title] OR kids[Title] OR child[Title] OR child*[Title] OR children*[Title] OR schoolchild*[Title] OR schoolchild[Title] OR school child[Title] OR school child*[Title] OR adolescen*[Title] OR juvenil*[Title] OR youth*[Title] OR teen*[Title] OR under*age*[Title] OR pubescen*[Title] OR pediatrics[MeSH] OR pediatric*[Title] OR paediatric*[Title] OR peadiatric*[Title])

CBZ → 37 results (01-08-2023)

VPA → 82 results (19-12-2023)

3. Pharmacokinetic studies

Table 3. Selected adult single-dose pharmacokinetic studies for carbamazepine model verification.

	Study	N	Dose	Administration	Health status	Age range (years)	% females	Ref
	Adult single dose							
A	Barzaghi et al. 1987	7	400 mg	Oral	Healthy volunteers	21-27	0	(4)
B	Bedada et al. 2015	12	200 mg	Oral	Healthy volunteers	25-30	0	(5)
C	Bedada et al. 2016	12	200 mg	Oral	Healthy volunteers	28-32	0	(6)
D	Bedada et al. 2017	12	200 mg	Oral	Healthy volunteers	25-33	0	(7)
E	Bernus et al. 1994	6	600 mg	Oral	Healthy volunteers	22-26	0	(8)
F	Chan et al. 1985	6	400 mg	Oral	Healthy volunteers	35.7 ± 8.3	NS	(9)
G	Dalton et al. 1985	8	600 mg	Oral	Healthy volunteers	24-35	0	(10)
H	Gerardin et al. 1976	6	100, 200, and 600 mg	Oral	Healthy volunteers	NS	0	(11)
I	Maas et al. 1987	11	200 mg	Oral	Healthy volunteers	21-30	54.5	(12)
J	Marino et al. 2012	2	500 mg q12h, 100 mg	Oral, 10 min IV	Epileptic subjects	41 ± 11	51.1	(13)
K	Pynnönen et al. 1977	6	400 mg	Oral	Healthy volunteers	21-22	0	(14)
L	Pynnönen et al. 1978	8	400 mg (A)	Oral	Healthy volunteers	23-30	NS	(15)
M	Wada et al. 1978	9	200 mg	Oral	Healthy volunteers	NS	0	(16)

Abbreviations: intravenously (IV), not specified (NS), number (N), reference (Ref), every 12 hours (q12h).

Table 4. Selected adult multi-dose pharmacokinetic studies for carbamazepine model verification.

Study	N	Dose	Administration	Health status	Age range (years)	% females	Ref
Adult multi dose							
A	Burstein et al. 2000	8	100 mg bid d1-3, 200 mg bid d4-6, and 400 mg qd d7-21	Oral	Healthy volunteers	24-43	37.5 (17)
B	Chan et al. 1985	10	200 mg bid d1-24	Oral	Healthy volunteers	40.2 ± 6.8	NS (9)
C	Gerardin et al. 1976	5	200 mg, after 96h 200 mg q24h d1-17	Oral	Healthy volunteers	NS	0 (11)
D	Ji et al. 2013	12	200 mg qd d1-3, 200 mg bid d4-6, and 400 mg qd d7-21	Oral	Healthy volunteers	18-45	30.6 (18)
E	Møller et al. 2000	12	100 mg bid d1-3, 200 mg bid d4-6, and 400 mg qd d7-21	Oral	Healthy volunteers	20-43	0 (19)
F	Moreno et al. 2004	14	200 mg q8h, >1 month	Oral	Epileptic women	21-44	100 (20)
G	Patsalos et al. 1990	12	1200, 1400, 1600, and 1800 mg TID (8.00, 13.00 and 20.00)	Oral	Subjects with severe refractory epilepsy	30-44	33.3 (21)
H	Tolbert et al. 2015	23	178.24 mg q6h	30 min IV	Types of epilepsy for which carbamazepine is indicated*	20-65	47.8 (22)
		41	163.48 mg q6h	15 min IV		23-68	53.7
		10	168.28 mg q6h	2-5 min IV		23-53	60.0

*i.e., partial seizures with complex symptomatology [e.g., psychomotor, temporal lobe], generalized tonic-clonic seizures [i.e., grand mal], mixed seizure patterns that include one of the previous seizure types, or other partial or generalized seizures. Abbreviations: two times a day (bid), day (d), intravenously (IV), not specified (NS), number (N), every day (qd), reference (Ref), every x hours (qhx).

Table 5. Selected pediatric pharmacokinetic single-dose studies for carbamazepine model verification

Study	N	Dose	Administration	Health status	Age range	% females	Ref
Pediatric single dose							
A	Bano et al. 1986	6	9.3 ± 0.87 mg/kg	Oral tablets	Healthy children	7-14 y	33.3 (23)
B	Bertilsson et al. 1980	2	2 mg/kg	Gelatin capsule	Children with psychomotor epilepsy	10-11 y	50 (24)
		1	3 mg/kg	Gelatin capsule		13 y	100
C	Mackintosh et al. 1987	6	5 mg/kg	Oral suspension	New-born infants with convulsions	GA 32-42w PNA 2-16d	50 (25)
D	Rey et al. 1979	7	17 mg/kg	Oral suspension	Newborns hospitalized for epilepsy	20.9 d	NS (26)
		5	19 mg/kg	Oral suspension	Children hospitalized for epilepsy	5.1 y	NS
E	Singh et al. 1996	10	10 mg/kg	Oral suspension	Term neonates in the NICU with 2 or more seizures	0-7 d	NS (27)

Abbreviations: days (d), gestational age (GA), number (N), neonatal intensive care unit (NICU), postnatal age (PNA), reference (Ref), weeks (w), year (y).

Table 6. Selected pediatric pharmacokinetic multi-dose studies for carbamazepine model verification

Study	N	Dose	Administration	Health status	Age range (years)	% females	Ref
Pediatric multi dose							
A Bertilsson et al. 1980	3	Custom	Oral tablets	Children with psychomotor epilepsy	10-13	66.6	(24)
B Camfield et al. 1992	15	6.75 mg/kg q12h (2.2-10.3 mg/kg) ^a	Oral tablets	Children with epilepsy	11±3 (5-16)	47.7	(28)
	1	200 mg q8h					
	1	200 mg at 9 AM, and 300 mg at 2 and 8 PM					
C Carlsson et al. 2005	52	7.35 mg/kg q12h (3.2-16.05 mg/kg) ^a	Oral suspension, IR and CR tablets	Pediatric patients with epilepsy	2-21 (2-18)	36.8	(29)
D Cornaggia et al. 1993	15	7.56 mg/kg at 9 AM, 3 and 9 PM (4.3-13.7 mg/kg) ^a	Oral tablets	Pediatric patients with EPS/CPS, secondarily generalized seizures, and GTCS	6-14	53.3	(30)
E Eeg-Olofsson et al. 1990	21	9.55 mg/kg q12h (10.0-35.3 mg/kg/day) ^a	Oral tablets	Pediatric patients with partial or GTCS	4-13	47.6	(31)
F Furlanut et al. 1984	45	6.3 mg/kg q8h	Oral tablets	Pediatric patients with GTCS, EPS and CPS	0.417-17	44.4	(32)
G Hartley et al. 1991	21	7.60 mg/kg q12h	Oral tablets	Pediatric patients with epilepsy	6.97-15.67	33.3	(33)
H Hartley et al. 1991a	12	10 mg/kg q12h	Oral tablets	Pediatric patients with GTCS or CPS	6.5-15	25.0	(34)
I Reith et al. 2000	6	13.85 mg/day (6.925 mg q12h)	Oral tablets	Children on carbamazepine treatment	4-10	42.9	(35)
	11				10-13		
	4				13-19		
J Thakker et al. 1992	12	233.3 mg 5h, 183.3 mg 4.8h, 183.3mg 3.3h, and 233.3 mg 10.9h	Oral tablets	Pediatric patients with chronic seizure disorder	8-17	0.25	(36)

^aAverage dose (range) Abbreviations: Controlled-release (CR), Generalised tonic-clonic seizures (GTCS), Elementary partial epileptic seizures (EPS), Complex partial epileptic seizures (CPS), Immediate-release (IR), every x hour (qxh), number (N), reference (Ref).

Table 7. Selected adult pharmacokinetic studies for valproic acid immediate-release model verification

Study	N	Dose (pure VPA)	Administration	Health status	Age range (years)	% females	Ref
1.1 Adult single dose							
A	Bialer et al. 1985	6	1000 mg (867.7)	Oral (Sodium VPA)	Healthy volunteers	20-35	0 (37)
G	Cheng et al. 2007	1	6.66 mg/kg (5.78)	Oral (Sodium VPA)	AML patient	NS	NS (38)
B	Chun et al. 1980	9	250 mg	Oral Capsule	Healthy volunteers	21-28	0 (39)
C	Georgoff et al. 2018	44	140 mg/kg (121.5) 130 mg/kg (112.8) 15 mg/kg (13.0)	1 hour IV infusion	Healthy volunteers	18-60	11.4 (40)
D	Gugler et al. 1977	6	600 mg (520.6)	Oral – Enteric coated	Healthy volunteers	23-26	16.7 (41)
E	Nitsche and Mascher 1982	6	1000 mg (867.7)	5 min IV bolus	Healthy volunteers	19-31	0 (42)
F	Perucca et al. 1978	6	800 mg (694.2) 800 mg (694.2)	Oral (Sodium VPA) 5 min IV bolus	Healthy volunteers	22-38	0 (43)
1.2 Adult multi dose							
A	Addison et al. 2000	7	200 mg q12h (173.5)	Oral (Sodium VPA)	Healthy volunteers	19-30	0 (44)
B	Cheng et al. 2007	1	6.66 mg/kg q8h (5.78)	Oral (Sodium VPA)	AML patient	NS	NS (38)
C	Hussein et al. 1994	18	750 mg (650.81) followed by 250 mg q6h (216.94)	1 hour IV infusion	Healthy volunteers	18-34	0 (45)

Abbreviations: acute myeloid leukemia (AML), intravenous (IV), not specified (NS), number (N), reference (Ref), every x hours (qhx).

Table 8. Selected pediatric pharmacokinetic studies for valproic acid immediate release model verification

Study	N	Dose (pure VPA)	Administration	Health status	Age range (years)	% females	Ref
1.1 Pediatric single dose							
A Alfonso et al. 2000	1	10 mg/kg	30 min IV infusion	Hypomelanosis	21 days	100	(46)
	1	25 mg/kg	30 min IV infusion	Epileptic	28 days	0	
B Cloyd et al. 1983	12	11.2 ± 6.9 mg/kg (9.72)	PO sodium VPA syrup	Children taking antiepileptics	1-14	59	(47)
C Hall et al. 1983	1	10.4 mg/kg (9.02)	PO sodium VPA ^a (syrup or capsule)	Pediatric patients with seizures	11	NS	(48)
	25	11.0 ± 3.7 mg/kg (9.54)					
D Visudtibhan et al. 2011	11	18.4 mg/kg (15.97)	6.13 min IV sodium VPA	Thai pediatric patients with varying underlying diseases	1-15	72.7	(49)
E Williams et al. 2012	10	15.0 mg/kg (13.02)	5 or 10 min IV sodium VPA	Epileptic	1-17	NS	(50)
F Brachet-Lierman & Demarquez 1977	1	100 mg/kg (86.8)	PO dipropylacetate	Epileptic	3 days	NS	(51)
1.2 Pediatric multi dose							
A Chiba et al. 1985	21	13.9 ± 3.55 mg/kg q12h (12.06)	PO sodium VPA (12 uncoated tablet/ 9 syrup)	Japanese epileptic children	3.6-15.2	52.4	(52)
B Cloyd et al. 1983	25	22.95 ± 13.1 mg/kg q12h (19.91)	PO sodium VPA syrup	Children taking antiepileptics	1-14	59	(47)
C Gal et al. 1988	5	20-25 mg/kg loading dose (19.52) , 5-10 mg/kg q12h maintenance (6.51)	PO Sodium VPA syrup	Neonates with intractable seizures	6-31 days	NS	(53)
D Hall et al. 1983	1	12.6 mg/kg q12h (10.93)	PO sodium VPA ^a (syrup or capsule)	Pediatric patients with seizures	11	NS	(48)
	25	16.4 ± 8.2 mg/kg q12h (14.23)					
E Hergren et al. 1991	7	14.83 ± 3.94 mg/kg q12h (12.87) 16.5 mg/kg q8h (14.32)	PO sodium VPA (solution/mixture)	Generalized epilepsies	0.5 – 1.5	29	(54)
F Lundberg et al. 1982	7	15.14 ± 3.53 mg/kg q12h (13.14)	PO sodium VPA tablets	Epileptic	6-13	28.6	(55)
	4	21.75 ± 10.80 mg/kg q8h (18.87)					
G Su et al. 2011	4	12.5 ± 3.5 mg/kg q12h (10.84)	PO syrup/capsules	Refractory solid/CNS tumors	3-21	61	(56)
H Zhao et al. 2016	75	19.63 ± 7.29 mg/kg q24h (17.03)	PO sodium VPA	Chinese epilepsy patients	0-3	44	(57)
	95	23.67 ± 9.21 mg/kg q24h (20.54)					

^aIt is assumed that sodium VPA is administered. Abbreviations: central nervous system (CNS), intravenous (IV), not specified (NS), number (N), reference (Ref), every x hours (q_xh).

Table 9. Selected adult pharmacokinetic studies for valproic acid extended-release formulation model verification

Study	N	Dose (pure VPA)	Administration	Health status	Age range (years)	% females	Ref
1.1 Adult single dose							
A	Dulac et al. 2005	22	500 mg	PO SR tablets	Healthy volunteers	18-34	0 (58)
B	Dutta et al. 2004A	15	500 mg	PO divalproex sodium ER tablets	Healthy volunteers	19-53	12.8 (59)
C	Dutta et al. 2004B	16	500 mg	PO divalproex sodium ER tablets	Healthy volunteers	18-50	37.5 (60)
D	Qiu et al. 2003	15	500 mg	PO divalproex sodium CR tablets	Healthy volunteers	NS	NS (61)
1.2 Adult multi dose							
A	Cawello et al. 2012	16	Day 1-3: 150 mg q12h (130.16) Day 4-17: 300 mg q12h (260.31)	PO SR tablets (Ergenyl Chrono 300)	Healthy volunteers	22-43	0 (62)
B	Dulac et al. 2005	22	500 mg q12h	PO SR tablets	Healthy volunteers	18-34	0 (58)
C	Dutta et al. 2002	35	1000 mg q24h 1500 mg q24h	PO divalproex sodium ER tablets	Healthy volunteers	19-55	36.1 (63)
D	Qiu et al. 2003	15	1000 mg q24h	PO divalproex sodium CR tablets	Healthy volunteers	NS	NS (61)

Abbreviations: controlled-release (CR), extended-release (ER), intravenously (IV), not specified (NS), number (N), reference (Ref), sustained-release (SR), every x hours (q_{xh}).

Table 10. Selected pediatric pharmacokinetic studies for valproic acid extended-release model verification

Study	N	Dose (pure VPA)	Administration	Health status	Age (years)	% females	Ref
1.2 Pediatric multi dose							
A	Dutta et al. 2004D	14	19.9 ± 8.54 mg/kg q24h	PO divalproex sodium ER tablets	Pediatric patients with migraine, bipolar disorder, ADHD or seizures	8-11	NS (64)
		12	14.4 ± 5.64 mg/kg q24h			13-17	
B	Herranz et al. 2006	48	11.3 ± 3.15 mg/kg q12h (9.81) 22.55 ± 6.25 mg/kg q24h (19.57)	PO SR valproate tablets (depakine chrono)	Pediatric patients with epilepsy	4.83-13.83	60.4 (65)
		11	11.95 ± 2.4 mg/kg q12h (10.37)			5.25-13.83	45.5
		11	29.1 ± 8.0 mg/kg q24h (25.25)			4.83-13.83	54.5
		11	23.7 ± 5.7 mg/kg q24h (20.56)			4.83-13.42	81.8

Abbreviations: attention-deficit hyperactivity disorder (ADHD), intravenously (IV), not specified (NS), number (N), reference (Ref), every x hours (q_{xh}).

4. Model verification

4.1 Model verification workflow and model performance assessment

Before model application, model performance need to be assessed via model verification. The verification workflow has been published earlier following a pragmatic approach (66, 67). In short, the CBZ and VPA PBPK models, as well as their metabolites, CBZE and 4-ene-VPA, respectively, were verified in the adult population. Simulations upon intravenous (IV) and oral (PO) administration (single and multidose) were compared with published PK data (Table S3, 4, 7 and 9). All simulations were conducted with 10 virtual subjects in 10 trials (i.e., n=100), unless stated otherwise below. In case steady state CBZ concentrations were obtained while no specific sampling day was indicated in the study, it was decided to run the simulations for 31 days and to compare the observed data with the predicted data from the last day.

Of note, for simulations where a 'Custom dosing scheme' or IV administration was applicable (also in simulations with children), CBZ was included in Simcyp as an 'Inhibitor' with CBZE as the 'Inhibitor Metabolite'. As CBZE elimination is partly parameterized as an Oral In Vivo Clearance (Table S1) was it incompatible with the custom dosing functionality when incorporated as 'Sub 1 Met'. The default Alfentanil model was applied as substrate, because there is no interaction between alfentanil and CBZ. Hence, alfentanil has no impact on predicted CBZ concentrations.

Next, simulations with pediatrics receiving IV or PO administrations were conducted and evaluated with clinical data (Table S5, 6, 8 and 10). CYP3A4 is the main metabolizing enzyme of CBZ, whereas VPA is mainly metabolized by UGT's. For CYP2C8, CYP2C9, CYP3A4, UGT1A4, UGT1A6, UGT1A9 and UGT2B7 are ontogeny profiles included (Figure S1), while for CYP3A5, UGT1A8 and UGT1A10 no ontogeny is included (i.e., fraction of adult activity is 1 for all ages). The 'redefine subjects over time' function was activated.

Specific CBZ virtual study designs which were not straight forward:

- For Patsalos et al. (21), four separate simulations were conducted where either 1200, 1400, 1600 or 1800 mg per day was administered orally. Then, plasma concentration-time data were combined to obtain a mean profile of the 4 different dosages to reflect the observed data (n=400).
- For Bertilsson et al. (24), for each separate child, an oral custom dosing scheme was simulated which were as follows: Subject A – Day 1: 2 mg/kg once, day 5-8: 2.62 mg/kg every 12 hours (q12h), day 26-146: 2.43 mg/kg q12h. Subject B – Day 1: 3 mg/kg once, day 5-8: 4.13 mg/kg q12h, day 9-12: 2.08 mg/kg at 9 AM and 4.13 mg/kg at 9 PM, day 13-153: 2.08 mg/kg q12h. Subject C – Day 1: 3 mg/kg once, day 5-38: 1.84 mg/kg at 9 AM and 3.71 mg/kg at 9 PM, day 39-162: 3.45 mg/kg q12h. Individual PK parameters are obtained from these simulations.

- For Camfield et al. (28), three separate simulations are conducted. One to derive PK parameters from (i.e., 6.75 mg/kg q12h) and two to derive individual plasma concentration-time profiles from to match to pediatric subjects (i.e., 200 mg q8h which is ‘subject 1’ and 200 mg at 9 AM, and 300 mg at 2 and 8 PM which is ‘subject 2’).

Specific VPA virtual study designs which were not straight forward:

- For Herranz et al. 2006 (65), observed data from VPA administration once daily in the morning and evening are represented in one simulation. As well as the 1 month and 4 months VPA concentration measurements are combined to one timepoint for each study.

Predictive performance of PBPK models was evaluated by 1) calculating the ratio of predicted-to-observed (p/o) PK parameters, and by 2) a visual predictive check (VPC). Ratios within 0.5 to 2-fold range were considered acceptable. For a visual check, observed plasma concentration-time profiles were extracted from literature, digitalized with WebPlotDigitizer v4.6, and compared to predicted plasma concentration-time curves.

4.2 Model verification results

For CBZ and CBZE predictions, the adult p/o PK ratios are shown in Figure S2, the pediatric ratios are shown in Figure S3, whereas for VPA the ratios upon IR administration are provided in Figure S4 and ratios upon ER administration in Figure S5. The percentages of p/o CBZ and CBZE PK ratios that fell within the 2-, 1.5-, and 1.25-fold range are provided in Table S11 and for VPA in Table S12. The VPCs for CBZ and CBZE predictions in adults are shown in Figure S6-7, in pediatrics in Figure S8-9, whereas for VPA IR in Figure S10-12 and for VPA ER in Figure S13-14.

Table 11. Carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) ratios within 2-, 1.5-, and 1.25-fold range.

	CBZ				CBZE			
	N	2-fold	1.5-fold	1.25-fold	N	2-fold	1.5-fold	1.25-fold
Adult single	53	66%	40%	23%	17	76%	35%	24%
Adult multi	40	100%	85%	53%	28	86%	54%	39%
Pediatric single	28	82%	43%	25%	0			
Pediatric multi	39	100%	90%	62%	14	79%	79%	71%

Table 12. Valproic acid (VPA) ratios within 2-, 1.5-, and 1.25-fold range.

	VPA IR				VPA ER			
	N	2-fold	1.5-fold	1.25-fold	N	2-fold	1.5-fold	1.25-fold
Adult single	33	93.9%	90.9%	63.6%	18	88.9%	61.1%	44.4%
Adult multi	8	100%	100%	87.5%	16	87.5%	87.5%	68.8%
Pediatric single	18	66.7%	61.1%	61.1%	0			
Pediatric multi	33	87.9%	48.5%	39.4%	10	100%	60.0%	50.0%




Figure 2. Predicted-to-observed ratios of the maximum concentration (C_{max}), minimum concentration (C_{min}), time to peak concentration (T_{max}), area under the curve (AUC), volume of distribution (Vd), clearance (CL), and half-life ($t_{1/2}$) for carbamazepine single- and multi-dose studies in adults. Single symbols represent a predicted-to-observed ratio of a single pharmacokinetic study. The black lines represent the 2-fold range, the dashed lines the 1.5-fold range, the gray shaded area represent the 1.25-fold range and the gray line represents the unity line.




Figure 3. Predicted-to-observed ratios of the maximum concentration (C_{max}), minimum concentration (C_{min}), average concentration (C_{av}), time to peak concentration (T_{max}), area under the curve (AUC), volume of distribution (V_d), clearance (CL), and half-life ($t_{1/2}$) for carbamazepine single- and multi-dose studies in **pediatrics**. Single symbols represent a predicted-to-observed ratio of a single pharmacokinetic study. The black lines represent the 2-fold range, the dashed lines the 1.5-fold range, the gray shaded area represent the 1.25-fold range and the gray line represents the unity line.




Figure 4. Predicted-to-observed ratios of the maximum concentration (C_{max}), average concentration (C_{av}), minimum concentration (C_{min}), time to peak concentration (T_{max}), area under the curve (AUC), volume of distribution (V_d), clearance (CL), and half-life ($t_{1/2}$) for valproic acid immediate release formulation single- and multi-dose studies in adults and pediatrics. Single symbols represent a predicted-to-observed ratio of a single pharmacokinetic study. The black lines represent the 2-fold range, the dashed lines the 1.5-fold range, the gray shaded area represent the 1.25-fold range and the gray line represents the unity line.




Figure 5. Predicted-to-observed ratios of the maximum concentration (C_{max}), minimum concentration (C_{min}), time to peak concentration (T_{max}), area under the curve (AUC), volume of distribution (V_d), clearance (CL), and half-life ($t_{1/2}$) for valproic acid extended-release formulations single- and multi-dose studies in adults and pediatrics. Single symbols represent a predicted-to-observed ratio of a single pharmacokinetic study. The black lines represent the 2-fold range, the dashed lines the 1.5-fold range, the gray shaded area represent the 1.25-fold range and the gray line represents the unity line.












Figure 6. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) plasma concentration-time profiles in adults upon single dose administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5th to 95th percentile of the virtual population. Open circles - the observed data: A (13), B (11), C (5-7, 11, 12, 16), D (5), E (4, 9, 14, 15), F (4), G (8, 10, 11), and H (8).






Figure 7. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) plasma concentration-time profiles in adults upon multi dose administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5th to 95th percentile of the virtual population. Open circles are the observed data: A-L (22), M & N (17, 19), O & P (9), Q (11), R & S (18), and T & U (21).











Figure 8. Prediction of carbamazepine (CBZ) and plasma concentration-time profiles in paediatric individuals upon single dose administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5th to 95th percentile of the virtual population. Open circles are the observed data: A (23), B (24), C (25), and D & E (26).














Figure 9. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) plasma concentration-time profiles in paediatric individuals upon multi dose administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5th to 95th percentile of the virtual population. Open circles are the observed data: A-D (28), E & F (31), G (29), H & I (33), J & K (34), and L & M (36).






Figure 10. Prediction of (unbound) valproic acid plasma concentration-time profiles in adults upon single-dose immediate-release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5th to 95th percentile of the virtual population. Open circles are the observed data: A & B (37), C (38), D (39), E-G (40), H (41), I (42), and J & K (43).












Figure 11. Prediction of valproic acid (VPA) and 4-ene-VPA plasma concentration-time profiles in adults upon multi-dose immediate-release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5th to 95th percentile of the virtual population. Open circles are the observed data: A & B (44), C & D (38), and E (45).






Figure 12. Prediction of valproic acid (VPA) plasma concentration-time profiles in pediatrics upon single- and multi-dose immediate release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5th to 95th percentile of the virtual population. Open circles are the observed data: A (48), B (49), C (50), D (48), E-H (54), I & J (55), and K (51).












Figure 13. Prediction of valproic acid (VPA) plasma concentration-time profiles in adults upon single- and multi-dose extended-release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5th to 95th percentile of the virtual population. Open circles are the observed data: A (58), B (59), C (60), D (61), E (62), F (58), and G & H (63).






Figure 14. Prediction of valproic acid (VPA) plasma concentration-time profiles in pediatrics upon multi-dose extended release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5th to 95th percentile of the virtual population. Open circles are the observed data: A-D (64) and E-I (65).

5. Simulating alternative dosing regimens

Methods

After model verification, the models were applied prospectively to evaluate current dosing strategies upon oral administration in children. The current CBZ dosing regimen for epilepsy, as provided in the Dutch Paediatric Formulary (DPF), was simulated (Figure S15-17) (68). Predicted exposures are compared to the therapeutic window of 4-12 µg/ml for CBZ (69), although concerns have been raised that levels above 8 µg/ml may result in reduced cognitive function in children (70). For CBZE, the upper boundary of the reference range, i.e., 2.3 µg/ml, is included (71). To note, for CBZ in the 5-12 year simulation, simulated children weighing over 50, 40, and 33.3 kg received 1000 mg/day after 2, 3, and 4 weeks after start of the therapy, respectively. This applied to 2, 7, and 8 virtual subjects, respectively.

The current VPA dosing regimen for epilepsy, as provided in the DPF, were simulated (Figure S19-23) (72). The same dosing strategies were simulated in term neonates (Figure S21 and 23). Predicted exposures were compared to the therapeutic window of 50-100 µg/ml for VPA (69). Based on reference concentrations of 50-100 µg/ml total VPA, reference values for the free fraction are 4-15 µg/ml (i.e., 7-9% unbound at 50 µg/ml and 15% at 100 µg/ml total concentrations) (3, 73). For 4-ene-VPA, the suggested upper boundary of the reference range, i.e., 0.5 µg/ml, is included (74).

In addition, to determine the effect of altered albumin levels in children and thereby potentially necessitating different dosing strategies, the mean VPA, unbound VPA, and 4-ene-VPA concentrations were simulated under +20%, normal, -20%, and -35% altered albumin level conditions (Figure S24). The coefficient of variance (CV) % was set to zero. In addition, the (hepatic) clearances (Figure S25) and volume of distributions were plotted (Figure S26).




Figure 15. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) concentrations following the current dosing guideline in children aged 12 to 16 and 16 to 18 years. The dose increases with 200 mg/day each week, with a maximum of 1000 mg/day and 1200 mg/day, respectively. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5th to 95th percentile of the virtual population. The blue shaded area indicates the CBZ therapeutic window (i.e., 4-12 µg/ml) and the red solid line indicates the CBZE upper boundary of the reference range (i.e., 2.3 µg/ml).




Figure 16. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) concentrations following the current dosing guideline in children aged 1 to 5 and 5 to 12 years. The dose increases with 5 mg/kg/day each week, with a maximum of 35 mg/kg/day and 1000 mg/day, respectively. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5th to 95th percentile of the virtual population. The blue shaded area indicates the CBZ therapeutic window (i.e., 4-12 µg/ml) and the red solid line indicates the CBZE upper boundary of the reference range (i.e., 2.3 µg/ml).




Figure 17. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) concentrations following the current dosing guideline in children aged 0 to 1 month and 1 month to 1 year. The dose increases with 5 mg/kg/day each week, with a maximum of 15 mg/kg/day (where the 7 mg/kg/day dosing regimen first changes to a 10 mg/kg/day regimen) and with a maximum of 35 mg/kg/day, respectively. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5th to 95th percentile of the virtual population. The blue shaded area indicates the CBZ therapeutic window (i.e., 4-12 $\mu\text{g/mL}$) and the red solid line indicates the CBZE upper boundary of the reference range (i.e., 2.3 $\mu\text{g/mL}$).




Figure 18. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) concentrations following the current and an adjusted dosing scheme in children aged 12 to 16 years and 16 to 18 years. The dose increases with 200 mg/day each week. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5th to 95th percentile of the virtual population. The blue shaded area indicates the CBZ therapeutic window (i.e., 4-12 µg/ml) and the red solid line indicates the CBZE upper boundary of the reference range (i.e., 2.3 µg/ml).




Figure 19. Prediction of valproic acid (VPA), unbound VPA, and 4-ene-VPA concentrations following the current dosing guideline in children aged 5 to 18 years. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5th to 95th percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 µg/ml), the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 µg/ml), and the red solid line indicates the 4-ene-VPA upper boundary of the reference range (i.e., 0.5 µg/ml).




Figure 20. Prediction of valproic acid (VPA), unbound VPA, and 4-ene-VPA concentrations following the current dosing guideline in children aged 1 month to 5 years. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5th to 95th percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 µg/ml), the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 µg/ml), and the red solid line indicates the 4-ene-VPA upper boundary of the reference range (i.e., 0.5 µg/ml).




Figure 21. Prediction of valproic acid (VPA), unbound VPA, and 4-ene-VPA concentrations following the current dosing guideline in children aged 0 to 1 month. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5th to 95th percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 $\mu\text{g/mL}$), the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 $\mu\text{g/mL}$), and the red solid line indicates the 4-ene-VPA upper boundary of the reference range (i.e., 0.5 $\mu\text{g/mL}$).




Figure 22. Prediction of valproic acid (VPA) and unbound VPA concentrations following the current extended release dosing guideline in children aged 1 month to 18 years. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5th to 95th percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 µg/ml) and the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 µg/ml).




Figure 23. Prediction of valproic acid (VPA) and unbound VPA concentrations following the current extended release dosing guideline in children aged 0 to 1 month without 'redefine subjects over time' function. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5th to 95th percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 µg/ml) and the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 µg/ml).




Figure 24. Prediction of valproic acid (VPA) and unbound VPA concentrations following 10 mg/kg immediate release VPA every 12 hours (q12h) in children aged 0 to 18 years with varying human serum albumin (HSA) levels. The lines are the predicted means of the simulated populations. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 µg/ml) and the green shaded area indicates the unbound VPA therapeutic window (i.e., 4-15 µg/ml).




Figure 25. Violin plots of predicted valproic acid clearance (CL) and hepatic clearance (CL_h) values upon either altered human serum albumin (HSA) levels, or altered doses, or both per simulated individual (n = 100, 12-18 years). Median levels are shown on top.




Figure 26. Predicted volume of distributions over time upon either altered human serum albumin (HSA) levels, or altered doses, or both. The lines are the predicted means of the simulated populations (n = 100, 12-18 years).




Figure 27. Predicted and observed valproic acid clearances (CL) corrected for body weight A) across the whole pediatric age range, and B) from 0 to 2 years old. The grey dots are individual predicted clearances after 3 weeks of treatment. For neonates, predicted clearances were provided upon a first dose and after 5 weeks of treatment. Observed data are either individual data points, or an average clearance with standard deviation across a certain age range., i.e., indicated with a connecting line. Observed data: Brachet-Liermain (51), Alfonso (46), Gal (53), Irvine-Meek (75), Herngren (54), Hall (48), Taylor (76), Kriel (77), Panomvana (78), Serrano (79), Cloyd (47), and Dutta (64).

6. References

1. Huang YT, Huang YM, Kung FL, Lin CJ, Jao T, Ho YF. Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact. *CPT Pharmacometrics Syst Pharmacol*. 2023;12(12):1960-71.
2. Conner TM, Nikolian VC, Georgoff PE, Pai MP, Alam HB, Sun D, et al. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex. *Eur J Pharm Sci*. 2018;111:465-81.
3. Cloyd JC, Dutta S, Cao G, Walch JK, Collins SD, Granneman GR. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. *Epilepsy Research*. 2003;53(1):19-27.
4. Barzaghi N, Gatti G, Crema F, Monteleone M, Amione C, Leone L, Perucca E. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. *Br J Clin Pharmacol*. 1987;24(6):836-8.
5. Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers. *Phytother Res*. 2015;29(5):701-6.
6. Bedada SK, Appani R, Boga PK. Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers. *Drug Res (Stuttg)*. 2017;67(1):46-51.
7. Bedada SK, Boga PK. Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects. *Xenobiotica*. 2017;47(10):879-84.
8. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Early stage autoinduction of carbamazepine metabolism in humans. *Eur J Clin Pharmacol*. 1994;47(4):355-60.
9. Chan KK, Sawchuk RJ, Thompson TA, Redalieu E, Wagner WE, Jr., LeSher AR, et al. Bioequivalence of carbamazepine chewable and conventional tablets: single-dose and steady-state studies. *J Pharm Sci*. 1985;74(8):866-70.
10. Dalton MJ, Powell JR, Messenheimer JA, Jr. The influence of cimetidine on single-dose carbamazepine pharmacokinetics. *Epilepsia*. 1985;26(2):127-30.
11. Gérardin AP, Abadie FV, Campestrini JA, Theobald W. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. *J Pharmacokinet Biopharm*. 1976;4(6):521-35.
12. Maas B, Garnett WR, Pellock JM, Comstock TJ. A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. *Ther Drug Monit*. 1987;9(1):28-33.
13. Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. *Clin Pharmacol Ther*. 2012;91(3):483-8.
14. Pynnönen S. The pharmacokinetics of carbamazepine in plasma and saliva of man. *Acta Pharmacol Toxicol (Copenh)*. 1977;41(5):465-71.
15. Pynnönen S, Mäntylä R, Iisalo E. Bioavailability of four different pharmaceutical preparations of carbamazepine. *Acta Pharmacol Toxicol (Copenh)*. 1978;43(4):306-10.

16. Wada JA, Troupin AS, Friel P, Remick R, Leal K, Pearmain J. Pharmacokinetic comparison of tablet and suspension dosage forms of carbamazepine. *Epilepsia*. 1978;19(3):251-5.
17. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. *Clin Pharmacol Ther*. 2000;68(6):605-12.
18. Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. *J Clin Pharmacol*. 2008;48(8):948-56.
19. Møller SE, Larsen F, Khant AZ, Rolan PE. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. *J Clin Psychopharmacol*. 2001;21(5):493-9.
20. Moreno J, Belmont A, Jaimes O, Santos JA, López G, Campos MG, et al. Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. *Arch Med Res*. 2004;35(2):168-71.
21. Patsalos PN. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients. *Br J Clin Pharmacol*. 1990;29(5):574-7.
22. Tolbert D, Cloyd J, Biton V, Bekersky I, Walzer M, Wesche D, et al. Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. *Epilepsia*. 2015;56(6):915-23.
23. Bano G, Raina RK, Sharma DB. Pharmacokinetics of carbamazepine in protein energy malnutrition. *Pharmacology*. 1986;32(4):232-6.
24. Bertilsson L, Höjer B, Tybring G, Osterloh J, Rane A. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. *Clin Pharmacol Ther*. 1980;27(1):83-8.
25. MacKintosh DA, Baird-Lampert J, Buchanan N. Is carbamazepine an alternative maintenance therapy for neonatal seizures? *Dev Pharmacol Ther*. 1987;10(2):100-6.
26. Rey E, d'Athis P, de Lauture D, Dulac O, Aicardi J, Olive G. Pharmacokinetics of carbamazepine in the neonate and in the child. *Int J Clin Pharmacol Biopharm*. 1979;17(2):90-6.
27. Singh B, Singh P, al Hifzi I, Khan M, Majeed-Saidan M. Treatment of neonatal seizures with carbamazepine. *J Child Neurol*. 1996;11(5):378-82.
28. Camfield P, Hwang P, Camfield C, Fraser A, Soldin S, al-Quadah AK. The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy. *Can J Neurol Sci*. 1992;19(2):204-7.
29. Carlsson KC, Hoem NO, Glauser T, Vinks AA. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. *Clin Ther*. 2005;27(5):618-26.
30. Cornaggia C, Gianetti S, Battino D, Granata T, Romeo A, Viani F, Limido G. Comparative pharmacokinetic study of chewable and conventional carbamazepine in children. *Epilepsia*. 1993;34(1):158-60.

31. Eeg-Olofsson O, Nilsson HL, Tonnby B, Arvidsson J, Grahn PA, Gylje H, et al. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations. *J Child Neurol.* 1990;5(2):159-65.
32. Furlanut M, Montanari G, Bonin P, Casara GL. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children. *J Pediatr.* 1985;106(3):491-5.
33. Hartley R, Forsythe WI, McLain B, Ng PC, Lucock MD. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. *Clin Pharmacokinet.* 1991;20(3):237-46.
34. Hartley R, Aleksandrowicz J, Bowmer CJ, Cawood A, Forsythe WI. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy. *J Pharm Pharmacol.* 1991;43(2):117-9.
35. Reith DM, Appleton DB, Hooper W, Eadie MJ. The effect of body size on the metabolic clearance of carbamazepine. *Biopharm Drug Dispos.* 2000;21(3):103-11.
36. Thakker KM, Mangat S, Garnett WR, Levy RH, Kochak GM. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients. *Biopharm Drug Dispos.* 1992;13(8):559-69.
37. Bialer M, Hussein Z, Raz I, Abramsky O, Herishanu Y, Pachys F. Pharmacokinetics of valproic acid in volunteers after a single dose study. *Biopharm Drug Dispos.* 1985;6(1):33-42.
38. Cheng H, Liu Z, Blum W, Byrd JC, Klisovic R, Grever MR, et al. Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2007;850(1-2):206-12.
39. Chun AH, Hoffman DJ, Friedmann N, Carrigan PJ. Bioavailability of valproic acid under fasting/nonfasting regimens. *J Clin Pharmacol.* 1980;20(1):30-6.
40. Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, et al. Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial. *Clin Pharmacokinet.* 2018;57(2):209-19.
41. Gugler R, Schell A, Eichelbaum M, Fröscher W, Schulz HU. Disposition of valproic acid in man. *Eur J Clin Pharmacol.* 1977;12(2):125-32.
42. Nitsche V, Mascher H. The Pharmacokinetics of Valproic Acid After Oral and Parenteral Administration in Healthy Volunteers. *Epilepsia.* 1982;23(2):153-62.
43. Perucca E, Gatti G, Frigo GM, Crema A. Pharmacokinetics of valproic acid after oral and intravenous administration. *Br J Clin Pharmacol.* 1978;5(4):313-8.
44. Addison RS, Parker-Scott SL, Eadie MJ, Hooper WD, Dickinson RG. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers. *Eur J Clin Pharmacol.* 2000;56(9-10):715-21.
45. Hussein Z, Mukherjee D, Lamm J, Cavanaugh JH, Granneman GR. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. *J Clin Pharmacol.* 1994;34(7):754-9.

46. Alfonso I, Alvarez LA, Gilman J, Dunoyer C, Yelin K, Papazian O. Intravenous valproate dosing in neonates. *J Child Neurol.* 2000;15(12):827-9.
47. Cloyd JC, Kriel RL, Fischer JH, Sawchuk RJ, Eggerth RM. Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy. *Neurology.* 1983;33(2):185-91.
48. Hall K, Otten N, Irvine-Meek J, Leroux M, Budnick D, Verma M, Seshia SS. First-dose and steady-state pharmacokinetics of valproic acid in children with seizures. *Clin Pharmacokinet.* 1983;8(5):447-55.
49. Visudtibhan A, Bhudhisawadi K, Vaewpanich J, Chulavatnatol S, Kaojareon S. Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. *Brain Dev.* 2011;33(3):189-94.
50. Williams JH, Jayaraman B, Swoboda KJ, Barrett JS. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. *J Clin Pharmacol.* 2012;52(11):1676-88.
51. Brachet-Liermain, A., et al, Pharmacokinetics of dipropyl acetate in infants and young children, *Pharmaceutisch Weekblad*, 1977, 112, 293-97.
52. Chiba K, Suganuma T, Ishizaki T, Iriki T, Shirai Y, Naitoh H, Hori M. Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. *J Pediatr.* 1985;106(4):653-8.
53. Gal P, Oles KS, Gilman JT, Weaver R. Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. *Neurology.* 1988;38(3):467-71.
54. Hergren L, Lundberg B, Nergårdh A. Pharmacokinetics of total and free valproic acid during monotherapy in infants. *J Neurol.* 1991;238(6):315-9.
55. Lundberg B, Nergårdh A, Boréus LO. Plasma concentrations of valproate during maintenance therapy in epileptic children. *J Neurol.* 1982;228(2):133-41.
56. Su JM, Li XN, Thompson P, Ou CN, Ingle AM, Russell H, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. *Clin Cancer Res.* 2011;17(3):589-97.
57. Zhao M, Zhang T, Li G, Qiu F, Sun Y, Zhao L. Simultaneous Determination of Valproic Acid and Its Major Metabolites by UHPLC-MS/MS in Chinese Patients: Application to Therapeutic Drug Monitoring. *J Chromatogr Sci.* 2017;55(4):436-44.
58. Dulac O, Alvarez JC. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration. *Pharmacotherapy.* 2005;25(1):35-41.
59. Dutta S, Zhang Y, Lee LL, O'Dea R. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers. *Biopharm Drug Dispos.* 2004;25(8):353-7.
60. Dutta S, Reed RC, Cavanaugh JH. Absolute Bioavailability and Absorption Characteristics of Divalproex Sodium Extended-Release Tablets in Healthy Volunteers. *The Journal of Clinical Pharmacology.* 2004;44(7):737-42.

61. Qiu Y, Cheskin HS, Engh KR, Poska RP. Once-a-Day Controlled-Release Dosage form of Divalproex Sodium I: Formulation Design and in Vitro/in Vivo Investigations. *Journal of Pharmaceutical Sciences*. 2003;92(6):1166-73.
62. Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. *J Clin Pharmacol*. 2012;52(11):1739-48.
63. Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. *Epilepsy Research*. 2002;49(1):1-10.
64. Dutta S, Zhang Y, Conway JM, Sallee FR, Biton V, Reed MD, Kearns GL. Divalproex-ER pharmacokinetics in older children and adolescents. *Pediatr Neurol*. 2004;30(5):330-7.
65. Herranz JL, Arteaga R, Adín J, Armijo JA. Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics. *Eur J Clin Pharmacol*. 2006;62(10):805-15.
66. van der Heijden JEM, Freriksen JJM, de Hoop-Sommen MA, van Bussel LPM, Driessen SHP, Orlebeke AEM, et al. Feasibility of a Pragmatic PBPK Modeling Approach: Towards Model-Informed Dosing in Pediatric Clinical Care. *Clin Pharmacokinet*. 2022;61(12):1705-17.
67. van der Heijden JEM, Freriksen JJM, de Hoop-Sommen MA, Greupink R, de Wildt SN. Physiologically-Based Pharmacokinetic Modeling for Drug Dosing in Pediatric Patients: A Tutorial for a Pragmatic Approach in Clinical Care. *Clin Pharmacol Ther*. 2023;114(5):960-71.
68. Kinderformularium. Kinderformularium - Carbamazepine [updated 15 July 2019] Date cited: 14 December 2023. Available from: <https://www.kinderformularium.nl/geneesmiddel/202/carbamazepine>.
69. Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. *Ther Drug Monit*. 2018;40(5):526-48.
70. Walson PD. Role of therapeutic drug monitoring (TDM) in pediatric anti-convulsant drug dosing. *Brain Dev*. 1994;16(1):23-6.
71. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs- best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2008;49(7):1239-76.
72. Kinderformularium. Kinderformularium - Valproïnezuur (Natriumvalproaat) [updated 17 October 2020] Date cited: 14 December 2023. Available from: <https://www.kinderformularium.nl/geneesmiddel/217/valproinezuur-natriumvalproaat>.
73. Nederlandse Vereniging van Ziekenhuisapothekers (NVZA). *TDM Monografie - Valproïnezuur* [Last updated: 08-03-2019]. Available from: <https://tdm-monografie.org/valproinezuur/> [
74. Kondo T, Kaneko S, Otani K, Ishida M, Hirano T, Fukushima Y, et al. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. *Epilepsia*. 1992;33(1):172-7.
75. Irvine-Meek JM, Hall KW, Otten NH, Leroux M, Budnik D, Seshia SS. Pharmacokinetic study of valproic acid in a neonate. *Pediatr Pharmacol (New York)*. 1982;2(4):317-21.

76. Taylor LM, Farzam F, Cook AM, Lewis DA, Baumann RJ, Kuhn RJ. Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients. *Pharmacotherapy*. 2007;27(4):519-25.
77. Kriel RL, Fischer JH, Cloyd JC, Green KH, Fraser GL. Valproic acid pharmacokinetics in children: III. Very high dosage requirements. *Pediatr Neurol*. 1986;2(4):202-8.
78. Panomvana Na Ayudhya D, Suwanmanee J, Visudtibhan A. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. *Am J Ther*. 2006;13(3):211-7.
79. Serrano BB, García Sánchez MJ, Otero MJ, Buelga DS, Serrano J, Domínguez-Gil A. Valproate population pharmacokinetics in children. *J Clin Pharm Ther*. 1999;24(1):73-80.